Home›Stock Screener›Shilpa Medicare›Intrinsic Value

Shilpa Medicare Intrinsic Value

Shilpa Medicare intrinsic value. Shilpa Medicare (SHILPAMED) median intrinsic value is ₹1801.40 from 10 valuation models (range ₹270–₹2252), vs current price ₹900.70 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Browse Shilpa Medicare financial data for revenue, profit, balance sheet and cash flow data.

Market Price (CMP)
₹900.70
Primary Intrinsic Value
₹356.40
Market Cap
₹1801 Cr
+100.0% Upside
Median Value
₹1801.40
Value Range
₹270 - ₹2252
Assessment
Trading Below Calculated Value
Safety Margin
50.0%

SHILPAMED Valuation Methods Summary — DCF, Graham Number & P/E

Shilpa Medicare intrinsic value across 10 models vs current price ₹900.70 — upside/downside and value range per method. For current market price and key ratios, visit SHILPAMED share price screener.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹356.40 ₹285.12 - ₹427.68 -60.4% EPS: ₹16.20, Sector P/E: 22x
Book Value Method asset ₹2251.75 ₹2026.58 - ₹2476.93 +150.0% Book Value/Share: ₹1295.50, P/B: 2.0x
Revenue Multiple Method revenue ₹1801.40 ₹1621.26 - ₹1981.54 +100.0% Revenue/Share: ₹1076.00, P/S: 2.0x
EBITDA Multiple Method earnings ₹1801.40 ₹1621.26 - ₹1981.54 +100.0% EBITDA: ₹604.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹2251.75 ₹1801.40 - ₹2702.10 +150.0% CF Growth: 15.0%, Discount: 15%
PEG Ratio Method growth ₹270.21 ₹243.19 - ₹297.23 -70.0% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹270.21 ₹243.19 - ₹297.23 -70.0% Revenue Growth: 6.0%, Adj P/E: 15.5x
ROE Based Valuation profitability ₹1801.40 ₹1621.26 - ₹1981.54 +100.0% ROE: 12.2%, P/E Multiple: 12x
Graham Defensive Method conservative ₹687.18 ₹618.46 - ₹755.90 -23.7% EPS: ₹16.20, BVPS: ₹1295.50
Dividend Yield Method dividend ₹270.21 ₹243.19 - ₹297.23 -70.0% DPS: ₹0.60, Target Yield: 2.5%
Method Types: Earnings Asset DCF Growth Dividend Conservative

SHILPAMED Intrinsic Value vs Market Price — All Valuation Models

Shilpa Medicare fair value range ₹270–₹2252 vs current market price ₹900.70 across 10 valuation models. Analyse SHILPAMED shareholder distribution to track promoter, FII and institutional holdings.

SHILPAMED Intrinsic Value Analysis — Undervalued or Overvalued?

Shilpa Medicare median intrinsic value ₹1801.40, current price ₹900.70 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.

What is the intrinsic value of SHILPAMED?

Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Shilpa Medicare (SHILPAMED) is ₹1801.40 (median value). With the current market price of ₹900.70, this represents a +100.0% variance from our estimated fair value.

The valuation range spans from ₹270.21 to ₹2251.75, indicating ₹270.21 - ₹2251.75.

Is SHILPAMED undervalued or overvalued?

Based on our multi-method analysis, Shilpa Medicare (SHILPAMED) appears to be trading below calculated value by approximately 100.0%.

SHILPAMED Financial Health — Key Ratios vs Industry Benchmarks

Shilpa Medicare financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 12.2% Industry Standard: 15%+ Above 10% Measures shareholder return efficiency
Operating Margin 27.0% Industry Standard: 20%+ Above 20% Indicates operational efficiency level
Asset Turnover Ratio 0.58x Industry Standard: 1.0x+ Above 0.5x Measures asset utilization efficiency

SHILPAMED Cash Flow Quality — Operating & Free Cash Flow

Shilpa Medicare operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹342 Cr ₹173 Cr Positive Free Cash Flow 8/10
March 2025 ₹132 Cr ₹33 Cr Positive Free Cash Flow 7/10
March 2024 ₹137 Cr ₹52 Cr Positive Free Cash Flow 7/10
March 2023 ₹180 Cr ₹64 Cr Positive Free Cash Flow 7/10
March 2022 ₹105 Cr ₹-38 Cr Positive Operating Cash Flow 6/10